Wegovy is the better option for weight loss because it’s specifically FDA-approved for weight management and delivers a higher maximum dose. Both medications contain the exact same active ingredient, semaglutide, made by the same manufacturer. The difference comes down to dosing and what they’re designed to treat. Wegovy tops out at 2.4 mg per week, while Ozempic maxes out at 2 mg, and that gap translates into meaningfully different results on the scale.
Same Drug, Different Purpose
Ozempic and Wegovy are both once-weekly injections of semaglutide, a compound that mimics a gut hormone your body naturally produces after eating. It works in two ways: it slows down how quickly food leaves your stomach, so you feel full longer, and it acts on appetite centers in the brain to reduce hunger and promote a sense of satiety. The drug also triggers the release of hormones involved in feeling satisfied after a meal.
Despite being chemically identical, the FDA approved them for different purposes. Wegovy is approved for weight management in adults and children 12 and older, for treating a form of fatty liver disease, and for reducing cardiovascular risk in adults with obesity or overweight who also have heart disease. Ozempic, on the other hand, is approved for managing Type 2 diabetes, improving kidney and cardiovascular health in adults with Type 2 diabetes and chronic kidney disease, and reducing heart risk in adults with Type 2 diabetes and heart disease.
This distinction matters more than it sounds. Because Ozempic isn’t FDA-approved for weight loss, prescribing it purely for that purpose is considered “off-label.” That affects insurance coverage, cost, and how your prescriber approaches treatment.
Why the Dose Difference Matters
The real performance gap between these two medications comes from dosing. Wegovy’s maintenance dose is 2.4 mg once weekly. Ozempic’s standard maintenance dose for diabetes is 1 mg, with an option to go up to 2 mg. That 20% jump from Ozempic’s ceiling to Wegovy’s target dose produces additional weight loss for most people.
In a 68-week clinical trial of nearly 2,000 adults with obesity (or overweight with at least one weight-related health problem), people taking Wegovy at the 2.4 mg dose lost an average of 15% of their body weight when combined with a reduced-calorie diet and increased physical activity. Ozempic trials, designed to measure blood sugar control rather than weight loss, consistently show lower average weight loss figures because participants are taking a lower dose of the same compound.
Both medications use a gradual dose increase to reduce side effects. If you’re starting Wegovy from scratch, you’ll begin at a low dose and step up over several months until you reach 2.4 mg. Patients already taking Ozempic at 1 mg can transition to Wegovy by starting at the 1 mg Wegovy dose for four weeks, moving to 1.7 mg for four weeks, then reaching the 2.4 mg maintenance dose. People on 2 mg of Ozempic who have been stable for at least four weeks can move directly to Wegovy 2.4 mg.
What Weight Loss Actually Looks Like
A 15% average weight loss means someone starting at 220 pounds could expect to lose roughly 33 pounds over about 16 months on Wegovy. But that’s an average. Individual responses vary considerably, and there’s no set timeline for when results become visible. Some people lose weight quickly in the first few months as their appetite drops; others see a slower, steadier decline.
Both drugs require ongoing lifestyle changes to work well. The clinical trials paired the medication with a reduced-calorie diet and more physical activity, and results without those components would be lower. Weight loss also tends to plateau after 12 to 16 months, and stopping the medication typically leads to weight regain, since the appetite-suppressing effects end when the drug clears your system.
Cost and Insurance Coverage
Wegovy’s list price sits around $1,350 per month, while Ozempic runs about $1,027 per month. In early 2025, Novo Nordisk announced plans to cut U.S. list prices for both drugs by up to 50%, though what you actually pay depends heavily on your insurance plan and pharmacy.
Getting insurance to cover either medication for weight loss can be complicated. For Wegovy, most commercial health plans require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like high blood pressure or sleep apnea. Some plans set the bar even higher. Eight out of eleven major plans reviewed by researchers at Tufts Medical Center also required patients to follow a reduced-calorie diet and exercise program. Seven required enrollment in a behavioral modification program before approving coverage, and one plan required patients to try a different weight loss medication first.
To keep your coverage active, nearly all plans require documented weight loss of at least 4% to 5% from your starting weight. If you don’t hit that threshold, your insurer may stop paying. Some employers exclude weight loss medications from their formularies entirely, regardless of what the insurance company’s public policy says.
Ozempic is generally easier to get covered if you have Type 2 diabetes, since that’s its approved use. But if you’re seeking it off-label for weight loss alone, insurers are unlikely to pay for it, and you may actually have an easier path getting Wegovy approved since it carries the weight management indication.
Supply and Availability
Semaglutide products experienced significant shortages in 2023 and 2024, driven by surging demand. As of early 2025, the FDA determined that the shortage of semaglutide injection products is resolved, confirming that the manufacturer’s production capacity can meet current and projected national demand. That said, you may still encounter occasional, localized supply disruptions as products move through distributors to local pharmacies.
Which One Should You Pursue
If your primary goal is weight loss and you don’t have Type 2 diabetes, Wegovy is the stronger choice. It’s approved for the purpose you need it for, it reaches a higher dose, and the clinical data supporting its weight loss results are built around that specific use. Getting a Wegovy prescription also gives you a clearer path through insurance approvals, since the FDA indication matches your reason for taking it.
If you have Type 2 diabetes and also want to lose weight, Ozempic handles both problems at once, though your weight loss may be somewhat less than what Wegovy could deliver at its higher dose. Some people in this situation start on Ozempic for blood sugar control and later transition to Wegovy if weight management becomes a bigger priority. That conversion is straightforward and well-documented in clinical practice.
The side effect profiles are nearly identical for both drugs, since they contain the same compound. Nausea, vomiting, diarrhea, and constipation are the most common issues, typically worst during the dose escalation phase and improving once your body adjusts. The gradual titration schedule exists specifically to minimize these effects.